Updated

New commentary examined whether Novo Nordisk shares represent a value trap or a bargain, weighing looming patent and competitive pressures on its semaglutide-based drugs against a stock trading at roughly a 10-times earnings multiple. The debate reflects growing investor uncertainty about the durability of Novo Nordisk's weight-loss and diabetes drug franchise as competition intensifies. The analysis underscores broader questions facing GLP-1 drugmakers as they navigate patent cliffs, pricing pressure and an increasingly crowded field of rival treatments.